Westover Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Westover Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-320	Closed	-$203K	–	240
2025 Q1	$203K	Hold	320	–	–	0.05%	230
2024 Q4	$228K	Hold	320	–	–	0.05%	216
2024 Q3	$336K	Hold	320	–	–	0.06%	192
2024 Q2	$336K	Hold	320	–	–	0.09%	164
2024 Q1	$308K	Hold	320	–	–	0.09%	142
2023 Q4	$281K	Hold	320	–	–	0.09%	146
2023 Q3	$263K	Hold	320	–	–	0.1%	149
2023 Q2	$230K	Hold	320	–	–	0.08%	164
2023 Q1	$263K	Hold	320	–	–	0.1%	140
2022 Q4	$231K	Hold	320	–	–	0.09%	138
2022 Q3	$220K	Buy	+320	New	+$201K	0.08%	145

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Westover Capital Advisors's REGN Position: Q2 2025 in Review

Westover Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 320 shares — an estimated $203K sold.

Westover Capital Advisors first reported a position in REGN in Q3 2022 and held it in 11 quarters. The position peaked at $336K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Westover Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Westover Capital Advisors sold 320 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $203K.
Westover Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2022 and held it in 11 quarters.
Westover Capital Advisors's Regeneron Pharmaceuticals position peaked at $336K in Q3 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Westover Capital Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.